• Nem Talált Eredményt

18 eredmény a kulcsszóra: 'systemic lupus erythematosus'

The clinical value of soluble urokinase plasminogen activator receptor (suPAR) levels in autoimmune connective tissue disorders

autoimmune disease, biomarker, inflammation, rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, systemic sclerosis, soluble urokinase

Protected

N/A

8
0
0
2022
Characterization of the thrombin generation profile in systemic lupus erythematosus

Keywords: thrombin generation, systemic lupus erythematosus, thrombosis, endogenous thrombin potential, anti-phospholipid

Protected

N/A

7
0
0
2022
PXK locus in systemic lupus erythematosus:

Since we detected neither splicing nor expression level changes, and no detrimental non-synonymous SNPs in the PXK gene that could be correlated with SLE association, this prompted

Protected

N/A

8
0
0
2022
A Antifoszfolipid-szindróma

Antiphospholipid antibodies in paediatric systemic lupus erythematosus, juvenile chronic arthritis and overlap syndromes: SLE patients with both lupus anticoagulant and

Protected

N/A

9
0
0
2022
C EfficacyofEculizumabinaPatientWithImmunoadsorption-DependentCatastrophicAntiphospholipidSyndrome:ACaseReport

The patient developed a subsequent flare of her systemic lupus erythematosus, potentially indicating that complement inhibition by eculizumab is not effective in preventing

Protected

N/A

5
0
0
2022
Off-label use of rituximab for systemic lupus erythematosus in Europe

Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy. van Vollenhoven RF,

Protected

N/A

8
0
0
2022
Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT)

Patients characterized with antinuclear antibodies (ANA) and disease symptoms related to one organ system can be described as having incomplete systemic lupus erythematosus

Protected

N/A

6
0
0
2022
Dry Eye and Corneal Langerhans Cells in Systemic Lupus Erythematosus

In our study a marked increase of dendritic cells could be demonstrated by in vivo confocal corneal microscopy in the central cornea even in the absence of clinically manifested

Protected

N/A

9
0
0
2022
Non-thromboembolic risk in systemic lupus erythematosus associated with antiphospholipid syndrome http://lup.sagepub.com/ Lupus

The aPL-positive patients exhibited a significantly higher morbidity than that for the aPL-negative patients, as indi- cated by the significantly higher total number of organ

Protected

N/A

7
0
0
2022
Antineutrophil Cytoplasmic Antibodies and Other Immunologic Abnormalities in Patients with Habitual Abortion

In systemic lupus erythematosus (SLE), an in- creased rate of spontaneous abortions may be ob- served even before the onset of the classical symptoms of the

Protected

N/A

7
0
0
2022
Összefoglaló a keszthelyi MKE Vándorgyűlés műszaki szekciójának munkájáról

Szepesi Judit Oktatás és tanulás online környezetben című előadásában a Könyvtári Intézet e-learning rendszerének tervezési folyamatát, az ezek által szerzett

Protected

N/A

2
0
0
2022
Serum concentration of immunoglobulin G-type antibodies against the whole Epstein–Barr nuclear antigen 1 and its aa35–58 or

Because no similar studies have been published in systemic lupus erythematosus (SLE) patients, we determined the HLA-DRB1*15:01 carrier state and the serum titres against the

Protected

N/A

8
0
0
2022
ReducedvolumesoftheCA1andCA4-dentategyrushippocampalsubfieldsinsystemiclupuserythematosus PAPER

SLE: systemic lupus erythemato- sus; MMSE: Mini-Mental State Examination; ACE: Addenbrooke’s Cognitive Assessment; SLEDAI: Systemic Lupus Disease Activity Index; SLICC/ACR DI:

Protected

N/A

5
0
0
2022
A magyar kereskedelmi jog kézikönyve

A tör- vény ez alatt nem érti azt, hogy a szövetkezet tagjai pusztán a társaság hasznaiban részesüljenek; hanem azt, hogy a szövetkezet egyenesen esz- köze legyen saját

Protected

N/A

2
0
0
2022
T cell and chemokine level change in systemic lupus erythematosus with pulmonary manifestation

Our data first described a significant positive correlation between peripheral CD4+CD25hi+ activated T cells and lung function parameters (FVC, FEV 1 ) and DL CO

Protected

N/A

19
0
0
2022
Systemic lupus erythematosus: clinical features in patients with a disease duration of over

attention to disease activity and the total end-organ insight is obtained about the real figures related to the number of patients going into remission and the number failure

Protected

N/A

6
0
0
2022
Psacharopoulos, G.: Az oktatás megtérülése

zési szint emelkedésével csökken a megté- rülési arány, valamint hogy az egyéniiés a társadalmi megtérülési arány közötti különb- ség mindegyik oktatási szinten nagyobb

Protected

N/A

2
0
0
2022
Duvergé, P.: Meteorológia és környezet

gazdaságtan egyik igen érdekes —- jelenleg is vitatott — kérdését, a fizikai és a szellemi tőke megtérülésének összehasonlitását2. az egyéni oktatási beruházások

Protected

N/A

2
0
0
2022

Töltsön fel további dokumentumokat, és töltse le azonnal az anyagtanulmányokat!